See every side of every news story
Published loading...Updated

Sensorion’s Gene Therapy for OTOF-Related Hearing Loss Progresses Following Positive Safety Review | Hearing Health & Technology Matters

Summary by hearinghealthmatters.org
MONTPELLIER, FRANCE — Sensorion (FR0012596468 – ALSEN), a clinical-stage biotechnology company specializing in novel therapies for hearing loss, announced that the Data Monitoring Committee (DMC) has recommended the continuation of the Audiogene Phase 1/2 clinical trial of SENS-501, a gene therapy program aimed at treating congenital deafness caused by OTOF (otoferlin) gene mutations. The DMC’s recommendation follows a review of safety data from…
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

All
Left
Center
Right
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

hearinghealthmatters.org broke the news in on Friday, February 21, 2025.
Sources are mostly out of (0)